Danielle Roman, PharmD, BCOP, FHOPA, explains how ASCO’s updated breast cancer surveillance guideline links follow-up intensity to recurrence risk and creates opportunities for pharmacist involvement.
Publication|Articles|October 19, 2026
Pharmacy Practice in Focus: Oncology
- October 2026
- Volume 8
- Issue 7
Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient mCSPC: Practical Considerations for Oncology Pharmacists
Fact checked by: Ron Panarotti
FDA-approved capivasertib triplet improves rPFS in PTEN-deficient mCSPC; learn dosing, key drug interactions, and managing diarrhea, hyperglycemia, and rash.
Advertisement
Advertisement
Prostate cancer is the most commonly diagnosed cancer in the United States.1 Although patients with localized prostate cancer have an excellent prognosis, those with metastatic disease can have a poor prognosis, especially those with adverse biomarkers such as RB1, TP53, BRCA1/2, and/or PTEN.2 Over the past decade, the standard of care for metastatic castration-sensitive prostate cancer (mCSPC, also called androgen pathway modulation-sensitive/naive prostate cancer) has evolved from androgen deprivation therapy (ADT) alone to treatment intensification with ADT plus an androgen receptor pathway inhibitor (ARPI), with docetaxel added for selected patients as part of triplet therapy.3 Recently, triplet approaches have emerged, namely ADT plus docetaxel and abiraterone (PEACE-1 trial; NCT01957436)/darolutamide (ARASENS trial; NCT02799602) or ADT plus niraparib and abiraterone/prednisone for BRCA2-mutated mCSPC (AMPLITUDE trial; NCT04497844).4-6
Related to this article
Isatuximab on-body injector enables quick, hyaluronidase-free subcutaneous dosing, reducing reactions and easing multiple myeloma clinic workflows.
After initial breast cancer treatment, pharmacists can help patients navigate ongoing endocrine therapy, manage persistent adverse effects, and address medication concerns that affect long-term care.
Five breast cancer treatment advances in 2026 expand therapeutic options while raising questions.
Peptide cancer vaccines target neoantigens to boost T cells, with promising melanoma and pancreatic trials hinting at a new era in immunotherapy.
Rather than requiring a new trial, the FDA extended evidence from carcinoma in situ to high-grade papillary-only disease, a new approach for this setting.
Nationwide Danish data presented at EASD 2026 link a widening cancer gap in type 2 diabetes largely to obesity-related cancers.
Peer Reviewed
Creating institution-specific, literacy-friendly chemotherapy education sheets resulted in patient education materials with higher readability scores than similar materials from common chemotherapy education sites.
Advertisement
Advertisement